A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers. - Related Studies

Home

Study Topics

Glossary


	Full Text View


	Tabular View


	Contacts and Locations


	No Study Results Posted


	Related Studies

A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers.

This study has been completed.

Study NCT00423566. Last updated on January 17, 2007. Information provided by University of Oxford

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Tuberculosis

2	More general conditions related to this trial
		Actinomycetales Infections
		Bacterial Infections
		Gram-Positive Bacterial Infections
		Mycobacterium Infections

3	Interventions listed in this trial
		MVA85A (Tuberculosis vaccine)

4	Sponsors listed in this trial
		University of Oxford